GlucoTrack

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell GlucoTrack and other ETFs, options, and stocks.

About GCTK

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements. 

CEO
Erik Emerson
CEOErik Emerson
Employees
15
Employees15
Headquarters
Rutherford, New Jersey
HeadquartersRutherford, New Jersey
Founded
2001
Founded2001
Employees
15
Employees15

GCTK Key Statistics

Market cap
5.92M
Market cap5.92M
Price-Earnings ratio
-0.03
Price-Earnings ratio-0.03
Dividend yield
Dividend yield
Average volume
47.74M
Average volume47.74M
High today
$0.5986
High today$0.5986
Low today
$0.4815
Low today$0.4815
Open price
$0.5131
Open price$0.5131
Volume
4.82M
Volume4.82M
52 Week high
$14.14
52 Week high$14.14
52 Week low
$0.25
52 Week low$0.25

Stock Snapshot

With a market cap of 5.92M, GlucoTrack(GCTK) trades at $0.51. The stock has a price-to-earnings ratio of -0.03.

During the trading session on 2026-08-06, GlucoTrack(GCTK) shares reached a daily high of $0.60 and a low of $0.48. At a current price of $0.51, the stock is +5.9% higher than the low and still -14.8% under the high.

Trading volume for GlucoTrack(GCTK) stock has reached 4.82M, versus its average volume of 47.74M.

The stock's 52-week range extends from a low of $0.25 to a high of $14.14.

The stock's 52-week range extends from a low of $0.25 to a high of $14.14.

GCTK News

TipRanks 6h
GlucoTrack Secures New Financing to Support Growth

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 14h
GlucoTrack announces $5.5M financing

Glucotrack (GCTK) announced definitive agreements for approximately $5.5M in financing from participating institutional investors, including a $2M equity financ...

TipRanks 6d
GlucoTrack Advances LT-100 to Single-Injection Development Strategy - TipRanks

...

GlucoTrack Advances LT-100 to Single-Injection Development Strategy - TipRanks

More GCTK News

Benzinga 7d
GlucoTrack Stock Surges Over 70% After Hours: Why is it Moving?

Single-Injection Strategy Fuels Rally The LT-100 program is a clinical development project evaluating Apitox, a purified honeybee venom biologic, as a treatmen...

GlucoTrack Stock Surges Over 70% After Hours: Why is it Moving?

People also own

Based on the portfolios of people who own GCTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.